Search results for "Immunization"
CDC and FDA weigh in on safety of bivalent vaccine; research examines COVID-19 sequelae, omicron variants
The CDC and FDA said an observed association of ischemic stroke with the Pfizer-BioNTech bivalent booster is very unlikely to represent a true clinical risk. New studies reported on symptoms a year after mild COVID-19 and estimated protection against the omicron variants.
https://immattersacp.org/weekly/archives/2023/01/24/2.htm
24 Jan 2023
New research on Pfizer pill, mental disorders after COVID-19, vaccine reactions
A manufacturer-funded trial quantified the effectiveness of nirmatrelvir/ritonavir in outpatients. A retrospective study found veterans had more mental health diagnoses and received more antidepressants, benzodiazepines, and opioids after COVID-19, while two other studies looked at reactions to second and third doses of the vaccines.
https://immattersacp.org/weekly/archives/2022/02/22/1.htm
22 Feb 2022
COVID-19 vaccine development must balance speed, safety
Multiple methods and numerous trials are underway in an attempt to develop a vaccine to end the COVID-19 pandemic.
https://immattersacp.org/archives/2020/06/COVID-19-vaccine-development-must-balance-speed-safety.htm
1 Jun 2020
New COVID-19 vaccine authorized; reviews analyze myocarditis, drug treatments
The FDA gave the Novavax COVID-19 vaccine emergency use authorization for adults. One recent review found lower myocarditis risk with the Pfizer-BioNTech vaccine than the Moderna vaccine, and another looked at the strength of evidence supporting COVID-19 drug treatments.
https://immattersacp.org/weekly/archives/2022/07/19/4.htm
19 Jul 2022
Study finds no link between autism, maternal flu vaccination during pregnancy
An accompanying editorial noted that a comprehensive and proactive approach to vaccine safety is needed now more than ever amid research into COVID-19 vaccines.
https://immattersacp.org/weekly/archives/2020/09/01/4.htm
1 Sep 2020
Pandemic enters new phase with end of PHE
COVID-19 isn't gone, but the end of the U.S. public health emergency does mark some significant changes.
https://immattersacp.org/archives/2023/06/pandemic-enters-new-phase-with-end-of-phe.htm
1 Jun 2023
High-dose flu vaccine may not be more effective than standard dose in patients with high-risk cardiovascular disease
An industry-funded randomized trial in the U.S. and Canada found no significant difference between a high-dose group versus a standard-dose group in the time to first occurrence of all-cause death or cardiopulmonary hospitalization during three flu seasons.
https://immattersacp.org/weekly/archives/2020/12/15/5.htm
15 Dec 2020
New COVID-19 boosters, DNA test for cancer risk OK’ed
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2023/11/new-covid-19-boosters-dna-test-for-cancer-risk-oked.htm
1 Nov 2023
Comprehensive study finds vaccines remarkably safe
The most common safety issue that resulted in label changes for vaccines was a restriction on the population to be vaccinated, such as pregnant or immunocompromised patients.
https://immattersacp.org/weekly/archives/2020/07/28/4.htm
28 Jul 2020
MKSAP Quiz: Evaluation for multiple myeloma
A 64-year-old man is evaluated following a recent diagnosis of multiple myeloma. Chemotherapy is planned to begin in 14 days. Which prophylactic therapy is indicated today?
https://immattersacp.org/weekly/archives/2023/12/05/3.htm
5 Dec 2023